Relmada Therapeutics, Inc.
Key Metrics
- Previous Close
- $3.01
- 52-Week Range
- $2.85 – $8.00
- Market Cap
- $304.61M
- P/E (TTM)
- —
- EPS (TTM)
- -0.73
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.57
- PEG Ratio
- —
- Return on Equity
- -64.66%
- Return on Assets
- -36.90%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 26.37
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-28.62M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $102.49M
Market Snapshot
About
Relmada Therapeutics is a clinical-stage biotechnology company developing novel medicines for the treatment of central nervous system diseases. The company is focused on developing esmethadone, a new chemical entity targeting treatment-resistant depression and other psychiatric conditions. Relmada uses its expertise in opioid receptor pharmacology to create non-addictive therapeutic candidates.